Healthcare & Medical

World Vaccine Congress Europe 2026

The World Vaccine Congress Europe brings experts from the whole value chain under one roof, you get to choose the sessions which are the most applicable to help your business plan for the future of vaccine research, development and manufacture.

Visit the official siteSponsorship open
31Speakers
24Sponsors
1Exhibitors
22On the bill · sessions
52Companies · in total
§I

Speakers

Programmed at World, in alphabetical order.
Amita Vaidya
Associate Director · Sanofi
Anna Saernefaelt
Global CMC Lead · CEPI
Arianna Marini
Associate Director, Global Clinical Immunology · IAVI
Biological E Limited
Damian Hiley
Managing Director, Vaccine Division · Desert King
Elissa R Weitzman
Associate Professor, Director of Research · Boston Children's Hospital, and Harvard Medical School
Emilie Karafillakis
European Director, Vaccine Confidence Project · London school of Hygiene and Tropical Medicine
Gautam Sanyal
Principal Consultant · Vaccine Analytics, LLC, USA
Gemma Lahuerta
Parenteral Development Director · LABORATORIO REIG JOFRE, S.A.
Giovanna Riggall
Head of Heath Supply Chain · Unimed
Heiko Keller
Supply Chain Manager · Center for Pandemic Vaccines and Therapeutics (ZEPAI) at Paul-Ehrlich-Institute (PEI)
Intravacc BV
Jeffrey Almond
Former VP Discovery R&D · Sanofi & Visiting Professor, University of Oxford
Jonathan Hare
Translational Science Lead · The Francis Crick Institute
Ligia Pinto
Directorate Director · Frederick National Laboratory for Cancer Research
Luigi Buonaguro
Lab director · National Cancer Institute
Maria Dutarte
Executive Director · EUPATI
Mats Lundgren
CSO · Abera Bioscience AB
Maxime Taquet
Associate Professor · University of Oxford
Mihai Bilanin
Global Regulatory Lead · GSK
Niall Macaulay
Policy Officer · Health Emergency Preparedness and Response Authority
Nico Vandaele
Prof. dr. · KU Leuven, Access-To-Medicines Research Centre
§II

Sponsors

The houses behind the program. Tiers as disclosed.
AsebioSupporting Partner
BactiVac NetworkSupporting Partner
BIOCATSupporting Partner
BioInsightsSupporting Partner
BioPartner U.K. LtdSupporting Partner
Biopharma AsiaSupporting Partner
ERCALSupporting Partner
EUPATISupporting Partner
Health-HollandSupporting Partner
hollandbioSupporting Partner
Immunity for HealthSupporting Partner
Immunization Economics Community of PracticeSupporting Partner
Infectious Disease AllianceSupporting Partner
Lab AtoZSupporting Partner
LYONBIOPOLESupporting Partner
MabDesignSupporting Partner
MarketsandMarketsSupporting Partner
NAVLIN Daily by EversanaSupporting Partner
Pharma Press GlobalSupporting Partner
Precision Vaccines ProgramSupporting Partner
touchIMMUNOLOGYSupporting Partner
touchINFECTIOUSDISEASESSupporting Partner
touchOPHTHAMOLOGYSupporting Partner
touchRESPIRATORYSupporting Partner
§III

Agenda

Selected from 22 sessions on the bill.
  • Oct 19 10:00

    BioNTech’s Oncology Pipeline: Combining mRNA Cancer Immunotherapies with Next-Gen Immunomodulators and Targeted Therapies

    Cancer & Therapeutic Vaccines
  • Oct 19 10:00

    Evolution of Drone Technology and Capacity Building Strategies

    Vaccine Supply & Logistics
  • Oct 19 10:00

    Workshop Leader’s Opening Remarks

    Platform Technologies
  • Oct 19 10:15

    A Versatile Platform Technology Enabling Development Of cVLP Vaccines Within Infectious & Non-Communicable Diseases

    Platform Technologies
  • Oct 19 10:15

    Cross-reactive cellular immunity and molecular mimicry in cancer

    Cancer & Therapeutic Vaccines
  • Oct 19 10:30

    From Forest to Finished GMP: Securing QS-21 for TB at Scale

    Vaccine Supply & Logistics
  • Oct 19 10:30

    Standardized Serology: A Critical Foundation for HPV Vaccine Development and Implementation

    Cancer & Therapeutic Vaccines
  • Oct 19 10:30

    Vaccine development using Outer Membrane Vesicle platform technology - TBC

    Platform Technologies
  • Oct 19 10:45

    Novel OMV platform for mucosal vaccines

    Platform Technologies
Intermission
Part the Second · For the Buyer

What does it mean when 52 companies show up, and 1 bet on three roles at once?

52 companies. one are betting more than once.

The numbers below are derived from the speakers, sponsors, and exhibitors on this page, cross-referenced into one ledger. They are the only thing here that 10times.com cannot tell you.

Who's in the room
1All threespeak · spons · exh
23Sponsoringsponsor only
1Exhibitingexhibitor only
27Companies Speakingspeaker only

The Triple-Threat

EUPATI

Speakers by seniority

58% of the speakers carry senior titles: C-suite, Founder, VP, or Director-level.

  • C-suite310%
  • Founder / Owner13%
  • VP-level310%
  • Director / Head of1135%
  • Manager / Lead516%
  • Research / Science13%
  • Other roles723%

Of 31 on the bill · classified by free-text title

Most-represented companies
  1. 01EUPATISp·S1V
  2. 02AsebioSp·S
  3. 03BactiVac NetworkSp·S
  4. 04BIOCATSp·S
  5. 05BioInsightsSp·S
  6. 06BioPartner U.K. LtdSp·S
  7. 07Biopharma AsiaSp·S
  8. 08ERCALSp·S
  9. 09Health-HollandSp·S
  10. 10hollandbioSp·S
  11. 11Immunity for HealthSp·S
  12. 12Immunization Economics Community of PracticeSp·S
  13. 13Infectious Disease AllianceSp·S
  14. 14Lab AtoZSp·S
Sponsors by tier
supporting partner24
100% of 24
Related events · by shared sponsors